ORYZON GENOMICS, S.A. «12345...» Página 3 de 11 desde 01/07/1988 hasta 26/09/2024 15/02/2019 16:03 ORYZON GENOMICS, S.A. Information on P&L Oryzon publish its 2018 final year results press release Número de registro: 274762 15/02/2019 15:43 ORYZON GENOMICS, S.A. Interim financial information La sociedad remite información sobre los resultados del segundo semestre de 2018 Número de registro: 274761 15/02/2019 15:19 ORYZON GENOMICS, S.A. Corporate governance annual report La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2018 Número de registro: 274760 02/11/2018 06:19 ORYZON GENOMICS, S.A. Interim financial information La sociedad remite información sobre los resultados del tercer trimestre de 2018 Número de registro: 271134 30/10/2018 18:37 ORYZON GENOMICS, S.A. Increases and decreases of share capital Oryzon Genomics, S.A. informs that on this day has granted a capital increase deed which has been duly registered with the Commercial Registry of Madrid. Número de registro: 271049 Relacionado con 270886 del 26/10/2018 (09:28) 26/10/2018 09:28 ORYZON GENOMICS, S.A. Increases and decreases of share capital The Company informs about the approval by the Board of Directors of a share capital increase, as well as about the procedure by means of which the private placement has been carried out and the results of said placement. Número de registro: 270886 Relacionado con 271049 del 30/10/2018 (18:37) 26/10/2018 09:28 ORYZON GENOMICS, S.A. Increases and decreases of share capital La compañía comunica información sobre una ampliación de capital con exclusión del derecho de suscripción preferente. Número de registro: 270885 17/10/2018 07:38 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Approval by the Spanish Medicines Agency (AEMPS) to conduct a PhIIa clinical trial with Iadademstat (ORY-1001). Número de registro: 270544 10/09/2018 17:50 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Approval by the Spanish Medicines Agency (AEMPS) to conduct a PhIIa clinical trial with ORY-1001. Número de registro: 269479 07/09/2018 07:30 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Approval by the Spanish Medicines Agency (AEMPS) to conduct a PhIIa clinical trial with Vafidemstat (ORY-2001). Número de registro: 269449 Página 3 de 11 «12345...»